Peptide Information
General Information of This Peptide
| Peptide ID |
PEP00012
|
|||||
|---|---|---|---|---|---|---|
| Peptide Name |
oxmCPPamph
|
|||||
| Structure |
|
|||||
| Sequence |
CGGWVELPPPVELPPPVELPPP
|
|||||
| Peptide Type |
Linear
|
|||||
| PDC Transmembrane Types | Cell-penetrating peptides (CPPs) | |||||
| Formula |
C111H167N23O29S
|
|||||
| Isosmiles |
[H]N[C@@H](CS[H])C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1cn([H])c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C
|
|||||
| InChI |
InChI=1S/C111H167N23O29S/c1-58(2)50-72(120-93(144)68(35-38-86(137)138)117-99(150)89(61(7)8)123-96(147)71(53-64-54-113-67-25-14-13-24-65(64)67)116-85(136)56-114-84(135)55-115-92(143)66(112)57-164)102(153)128-43-17-28-77(128)107(158)131-46-20-31-80(131)105(156)126-41-15-26-75(126)97(148)124-90(62(9)10)100(151)118-69(36-39-87(139)140)94(145)121-73(51-59(3)4)103(154)129-44-18-29-78(129)108(159)132-47-21-32-81(132)106(157)127-42-16-27-76(127)98(149)125-91(63(11)12)101(152)119-70(37-40-88(141)142)95(146)122-74(52-60(5)6)104(155)130-45-19-30-79(130)109(160)133-48-22-33-82(133)110(161)134-49-23-34-83(134)111(162)163/h13-14,24-25,54,58-63,66,68-83,89-91,113,164H,15-23,26-53,55-57,112H2,1-12H3,(H,114,135)(H,115,143)(H,116,136)(H,117,150)(H,118,151)(H,119,152)(H,120,144)(H,121,145)(H,122,146)(H,123,147)(H,124,148)(H,125,149)(H,137,138)(H,139,140)(H,141,142)(H,162,163)/t66-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,89-,90-,91-/m0/s1
|
|||||
| InChIKey |
XJVVDKKMICMFLT-HXPPUVHPSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
2319.756
|
Polar area
|
723
|
||
|
Complexity
|
2318.202077
|
xlogp Value
|
-1.2478
|
|||
|
Heavy Count
|
164
|
Rot Bonds
|
57
|
|||
|
Hbond acc
|
27
|
Hbond Donor
|
19
|
|||
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
DOXoxmCPPamph [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
19 μM
|
|||
| Description |
Doxorubicin binds with high affinity to DNA by intercalation, which leads to DNA damage and subsequent growth inhibition44,45. We performed MTT assays in order to determine the viability of the tumor cells and additionally to assess the proliferative potential of the cells after drug treatment. MCF-7 and HT-29 cells were incubated with doxorubicin and the peptide conjugates at various concentrations in the range of 0.1 and 50 μmfor 72 h (in a serum-containing medium), and the results were expressed as IC50-values (Table 1).
Click to Show/Hide
|
||||
| In Vitro Model | Colon cancer | HT29 cell | CVCL_A8EZ | ||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
24.7 μM
|
|||
| Description |
Doxorubicin binds with high affinity to DNA by intercalation, which leads to DNA damage and subsequent growth inhibition44,45. We performed MTT assays in order to determine the viability of the tumor cells and additionally to assess the proliferative potential of the cells after drug treatment. MCF-7 and HT-29 cells were incubated with doxorubicin and the peptide conjugates at various concentrations in the range of 0.1 and 50 μmfor 72 h (in a serum-containing medium), and the results were expressed as IC50-values (Table 1).
Click to Show/Hide
|
||||
| In Vitro Model | Colon cancer | HT29 cell | CVCL_A8EZ | ||
References